An open-label Truvada pre-exposure prophylaxis (PrEP) demonstration project, which included more than 500 mostly gay and bisexual men in San Francisco, Miami, and Washington, DC, showed that adherence was generally good overall -- especially among people at highest risk for HIV infection -- but there were some important disparities, researchers reported at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention in Vancouver.
HIVandHepatitis.com coverage of the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), July 19-22, in Vancouver, Canada.
Conference highlights include HIV treatment as prevention, pre-exposure prophylaxis (PrEP), new antiretroviral therapies, HIV cure research, hepatitis C and HIV/HCV coinfection, and global scale-up of prevention and treatment.
While adolescents and young adults are about as likely as older people to be linked to care after being diagnosed with HIV, less than a third were retained in care or started antiretroviral therapy (ART), and only 7% reached undetectable viral load -- much lower than the rate for older individuals, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last month in Vancouver. Prompt referral to youth-friendly services, however, increased the likelihood of viral suppression.
On July 30 the White House released an updated version of its National HIV/AIDS Strategy, outlining the administration's plans through the year 2020. In keeping with recent research, the revised strategy includes an increased emphasis on early antiretroviral treatment and pre-exposure prophylaxis (PrEP), as well as focusing on underserved and heavily affected population groups including young gay men, transgender women, and African-Americans.